US4689224A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for administering vaccines containing equine leukokines and compositions therefor
Assignee: Neogen Corp
•
Filing: 1986-09-10
•
Granted: 1987-08-25
•
Expires: 2006-09-10
Abstract
Abstract A method for enhancing a vaccine immune response in mammals, including mice, equines, canines and felines using leukokines, particularly mixed leukokines, is described. The leukokines can be administered separately or admixed with the vaccine. The method and vaccine compositions are particularly effective where equine influenza vaccine or canine parvovirus vaccine and mixed leukokines are administered together to the equine or canine.
Inventors
- 👤 Robert W. Bull
- 👤 Robert M. Soltysiak
- 👤 Paul D. Minnick
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 23:40
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/39; A61K45/00; A61K45/05; A61K2039/555; A61K2039/55511; A61K2039/55522
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
59 words
In a method for providing an immune response to a disease in a mammal with a viral or viral subunit or other viral antigen vaccine which produces a blood serum antibody response to the vaccine in the mammal the improvement which comprises: administering an equine leukokine with the vaccine to thereby provide an enhanced immune response in the mammal.
Claim 2
Dependent Claim
59 words
In a method for providing an immune response to a disease in a mammal with a viral or viral subunit or other viral antigen vaccine which produces a blood serum antibody response to the vaccine in the mammal the improvement which comprises: administering an equine leukokine with the vaccine to thereby provide an enhanced immune response in the mammal.
Claim 3
Dependent Claim
19 words
The method of claim 1 wherein the vaccine and leukokine are administered concurrently or in admixture to the mammal.
Claim 4
Dependent Claim
30 words
The method of claim 1 wherein prior to administration the leukokine has been induced by a virus in a medium containing leucocytes and then separated from the medium and leucocytes.
Claim 5
Dependent Claim
17 words
The method of claim 3 wherein the virus which induced the leukokine produces Newcastles disease in chickens.
Claim 6
Dependent Claim
19 words
The method of claim 1 wherein the vaccine is for canine parvovirus and is injected intramuscularly with the leukokine.
Claim 7
Dependent Claim
24 words
The method of claim 5 wherein an amount of at least 100 IPU of the leukokine are administered to the mammal with the vaccine.
Claim 8
Dependent Claim
15 words
The method of claim 1 wherein the leukokine and vaccine are administered separately and concurrently.
Claim 9
Dependent Claim
14 words
The method of claim 1 wherein the vaccine and leukokines are administered by injection.
Claim 10
Dependent Claim
39 words
The method of claim 1 wherein the administration is by injection, wherein the vaccine and leukokine are administered separately and concurrently and wherein the leukokine is induced in the leucocytes by a virus which produces Newcastles disease in chickens.
Claim 11
Dependent Claim
17 words
The method of claim 1 wherein the leukokine is an admixture of leukokines of different molecular size.
Claim 12
Dependent Claim
81 words
A vaccine composition for a mammal which comprises in admixture: (a) a viral or viral subunit or other viral antigen vaccine which provides a blood serum antibody response to the vaccine in the mammal to provide an immune response to a viral disease; and (b) an equine leukokine as an adjuvant to the vaccine, wherein the leukokine is present in an amount of at least about 100 IPU which enhances the blood serum antibody response to the vaccine in the mammal.
Claim 13
Dependent Claim
81 words
A vaccine composition for a mammal which comprises in admixture: (a) a viral or viral subunit or other viral antigen vaccine which provides a blood serum antibody response to the vaccine in the mammal to provide an immune response to a viral disease; and (b) an equine leukokine as an adjuvant to the vaccine, wherein the leukokine is present in an amount of at least about 100 IPU which enhances the blood serum antibody response to the vaccine in the mammal.
Claim 14
Dependent Claim
29 words
The vaccine composition of claim 11 wherein the leukokine prior to admixture has been induced by a virus in a medium containing leucocytes and then separated from the medium.
Claim 15
Dependent Claim
18 words
The vaccine composition of claim 12 wherein the virus which induced the leukokine produces Newcastles disease in chickens.
Claim 16
Dependent Claim
18 words
The vaccine composition of claim 11 wherein the leukokines are a mixture of leukokines of different molecular size.
Claim 17
Dependent Claim
77 words
A parvovirus vaccine composition for a canine which comprises in admixture: (a) a parvovirus vaccine which produces a blood serum antibody response to the vaccine in the canine to provide parvovirus immunity; and (b) an equine leukokine as an adjuvant to the vaccine, wherein the leukokine is present in an amount of at least about 100 IPU which enhances the blood serum antibody response to the vaccine in the canine by providing immunity at an earlier age.
Claim 18
Dependent Claim
77 words
A parvovirus vaccine composition for a canine which comprises in admixture: (a) a parvovirus vaccine which produces a blood serum antibody response to the vaccine in the canine to provide parvovirus immunity; and (b) an equine leukokine as an adjuvant to the vaccine, wherein the leukokine is present in an amount of at least about 100 IPU which enhances the blood serum antibody response to the vaccine in the canine by providing immunity at an earlier age.
Claim 19
Dependent Claim
21 words
The vaccine composition of claim 15 wherein between about 100 and 5000 IPU of the leukokines in the vaccine are administered.
Claim 20
Dependent Claim
20 words
The vaccine composition of claim 16 wherein the vaccine is administered in a dosage between about 0.1 and 5 ml.
References Cited (Backward Citations)
US3699222A
Cited
US3518347A
Cited
US3790665A
Cited
US3793150A
Cited
US3906092A
Cited
US3919411A
Cited
US4009258A
Cited
US3970749A
Cited
US4503035A
Cited
US4503035B1
Cited
US4303645A
Cited
US4466957A
Cited
US4619827A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-08-24 | 1991-02-23 | 1991-08-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-08-24 | 1995-02-23 | 1995-08-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-08-24 | 1999-02-23 | 1999-08-25 | $7700.00 | Window Closed / Lapsed |